18f-pf-06445974
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 22, 2023 (NCT05703685)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 4BRadiopharmaceutical
PDE4B radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07027839 | Phase 1 | Dec 2, 2025 | National Institute of Mental Health (NIMH) |
| NCT07169630 | Phase 1 | Dec 2, 2025 | National Institute of Mental Health (NIMH) |
| NCT06795581 | Phase 1 | Mar 20, 2025 | National Institute of Mental Health (NIMH) |
| NCT05703685 | Phase 1 | Jun 22, 2023 | National Institute of Mental Health (NIMH) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 4 | 4 | 1 | 2023 |
1 organizations
Page 1 / 1